Floatz logo

Lonafarnib

Metastases, Neoplasm

Merck Sharp & Dohme LLCSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Metastases, Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Lonafarnib is also rated in:

Hutchinson-Gilford progeria syndromeDormant
B
Indicative ·
58 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
carcinoma of urethraDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →